Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AKBA

Why Akebia Therapeutics Stock Is Soaring After Hours

Akebia Therapeutics Inc (NASDAQ: AKBA) shares are surging in Thursday's after-hours session after the company executed an agreement to terminate its Vadadustat collaboration and license agreements with Otsuka Pharmaceutical.

Looking Into Akebia Therapeutics's Return On Capital Employed

Looking Into Akebia Therapeutics's Return On Capital Employed

According to Benzinga Pro data, during Q1, Akebia Therapeutics (NASDAQ:AKBA) posted sales of $61.70 million. Earnings were up 11.68%, but Akebia Therapeutics still reported an overall loss of $62.42 million.

Why Are Akebia Therapeutics Shares Falling Today?

Why Are Akebia Therapeutics Shares Falling Today?

Akebia Therapeutics Inc (NASDAQ:AKBA) and Otsuka Holdings (OTC: OTSKY) separately announced to call for licensing and co-development agreement for vadadustat. Otsuka sent a written notice to Akebia on May 12 that the partnership had been terminated. Akebia said in an SEC filing filed Friday that the termination will go into effect in a year.…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Expert Ratings for Akebia Therapeutics

Over the past 3 months, 4 analysts have published their opinion on Akebia Therapeutics (NASDAQ:AKBA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

See Why Does HC Wainwright Maintain Neutral On Akebia Stock

Akebia Therapeutics Inc (NASDAQ: AKBA) announced three poster presentations at the National Kidney Foundation (NKF) Spring Clinical Meetings 2022.

FDA Places Partial Hold On Vadadustat Pediatric Studies, Akebia Cuts Over 40% Staff

Battered after a surprising FDA rejection for its lead pipeline program last week, Akebia Therapeutics Inc (NASDAQ:AKBA) has layoffs that are now on the way. In a filing with the SEC, Akebia said the FDA issued a partial clinical hold on the drug's pediatric studies. As a result, Akebia will suspend all vadadustat studies…

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022

inkl

Read news from The Economist, FT, and more,
with one subscription

FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia

FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia

The FDA has issued a complete response letter (CRL) to Akebia Therapeutics Inc's (NASDAQ:AKBA) marketing application (NDA) for vadadustat for anemia due to chronic kidney disease (CKD). Vadadustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. The FDA issues a CRL to indicate that the review cycle for an application is complete…

Akebia Therapeutics Earnings Perspective: Return On Capital Employed

Akebia Therapeutics Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Akebia Therapeutics (NASDAQ:AKBA) reported Q4 sales of $59.60 million. Earnings fell to a loss of $70.68 million, resulting in a 18.7% decrease from last quarter.

Recap: Akebia Therapeutics Q4 Earnings

Recap: Akebia Therapeutics Q4 Earnings

Akebia Therapeutics (NASDAQ:AKBA) reported its Q4 earnings results on Tuesday, March 1, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Organisations

Advanced Micro Devices

Dell Technologies

Coinbase Global

Canaccord Genuity

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

354,142 stories

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play